Wall Street analysts predict that Xeris Pharmaceuticals Inc (NASDAQ:XERS) will announce $2.17 million in sales for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Xeris Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $1.80 million and the highest estimate coming in at $2.70 million. Xeris Pharmaceuticals reported sales of $310,000.00 during the same quarter last year, which would suggest a positive year over year growth rate of 600%. The company is expected to announce its next earnings results on Tuesday, August 4th.
According to Zacks, analysts expect that Xeris Pharmaceuticals will report full-year sales of $15.01 million for the current financial year, with estimates ranging from $12.30 million to $18.10 million. For the next financial year, analysts anticipate that the firm will post sales of $59.43 million, with estimates ranging from $54.10 million to $64.40 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Xeris Pharmaceuticals.
Xeris Pharmaceuticals (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.89) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.92) by $0.03. Xeris Pharmaceuticals had a negative return on equity of 323.82% and a negative net margin of 3,100.00%. The business had revenue of $1.68 million during the quarter, compared to the consensus estimate of $1.82 million.
XERS traded up $0.17 on Monday, reaching $2.68. The company’s stock had a trading volume of 3,332,848 shares, compared to its average volume of 787,454. The stock has a 50 day moving average of $4.64 and a two-hundred day moving average of $4.49. The company has a quick ratio of 4.72, a current ratio of 4.82 and a debt-to-equity ratio of 2.16. The company has a market capitalization of $94.35 million, a price-to-earnings ratio of -0.56 and a beta of 2.10. Xeris Pharmaceuticals has a fifty-two week low of $1.42 and a fifty-two week high of $12.94.
In other news, insider Paul R. Edick acquired 33,000 shares of Xeris Pharmaceuticals stock in a transaction on Friday, May 8th. The stock was bought at an average price of $3.54 per share, for a total transaction of $116,820.00. Following the completion of the purchase, the insider now owns 95,493 shares in the company, valued at $338,045.22. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John Patrick Shannon, Jr. acquired 22,000 shares of Xeris Pharmaceuticals stock in a transaction on Wednesday, May 13th. The stock was purchased at an average price of $3.55 per share, with a total value of $78,100.00. Following the purchase, the insider now owns 117,493 shares of the company’s stock, valued at approximately $417,100.15. The disclosure for this purchase can be found here. 5.95% of the stock is currently owned by insiders.
Institutional investors have recently added to or reduced their stakes in the company. M&T Bank Corp lifted its position in Xeris Pharmaceuticals by 20.8% during the fourth quarter. M&T Bank Corp now owns 20,543 shares of the company’s stock worth $145,000 after buying an additional 3,540 shares during the period. Deutsche Bank AG raised its holdings in shares of Xeris Pharmaceuticals by 40.7% during the 1st quarter. Deutsche Bank AG now owns 13,617 shares of the company’s stock valued at $27,000 after buying an additional 3,942 shares during the period. American International Group Inc. raised its holdings in shares of Xeris Pharmaceuticals by 26.3% during the 1st quarter. American International Group Inc. now owns 21,090 shares of the company’s stock valued at $41,000 after buying an additional 4,394 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Xeris Pharmaceuticals by 8.7% during the 4th quarter. Bank of New York Mellon Corp now owns 83,352 shares of the company’s stock valued at $588,000 after buying an additional 6,648 shares during the period. Finally, Marshall Wace North America L.P. purchased a new stake in shares of Xeris Pharmaceuticals during the 1st quarter valued at about $71,000. Institutional investors and hedge funds own 62.48% of the company’s stock.
About Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Featured Article: Why do analysts give a neutral rating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.